Trial reportArchives of disease in childhood2013
Acceptability of different oral formulations in infants and preschool children.
Trial report in Archives of disease in childhood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07424495 (Chewable Tablets Produced by Three-Dimensional Printing), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chewable Tablets Produced by Three-Dimensional Printing: A Sensory Acceptability Study in Children and Adolescents
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- Methodology Used to Assess Acceptability of Oral Pediatric Medicines: A Systematic Literature Search and Narrative Review.Paediatric drugs · 2017Pooled it
- Acceptability of placebo multiparticulate formulations in children and adults.Scientific reports · 2018Trial
- In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir.British journal of clinical pharmacology · 2017Trial
- How Children with Kawasaki Disease Take Acetylsalicylic Acid Mini-Tablets at Home for the Prescribed Period.Journal of clinical medicine · 2025Article
- Innovative applications of 3D printing in personalized medicine and complex drug delivery systems.iScience · 2025Review
- Choosing the "Ideal" Oral Dosage Form for Pediatric Patients: Parents' Perspectives on Children's Preferences with a Focus on Orodispersible Tablets.Children (Basel, Switzerland) · 2025Article
- Film Coating of Small Molded Tablets for Pediatric Formulations with Rapid Disintegration and Bitterness-Masking Properties.Molecules (Basel, Switzerland) · 2025Article
- Concept and Evolution in 3D Printing for Excellence in Healthcare.Current medicinal chemistry · 2025Review
- Acceptability of minitablets in soft food. A randomised cross-over study in children.Frontiers in pharmacology · 2025Article
- Evaluation of marketing authorization and labels of medicines in 2021 WHO Model List of Essential Medicines for Children in China, the Russian Federation and Brazil.Health research policy and systems · 2024Article
- The Past, Present, and Future of Oral Dosage Forms for Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024Article
- Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data.PharmacoEconomics - open · 2023Article
- Manufacturing pharmaceutical mini-tablets for pediatric patients using drop-on-demand printing.International journal of pharmaceutics · 2023Article
- Stability of Oral Liquid Dosage Forms in Pediatric Cardiology: A Prerequisite for Patient's Safety-A Narrative Review.Pharmaceutics · 2023Review
- Compounding of Liquid and Solid Dose Adjustable Formulations with Pantoprazole: Comparison of Stability, Applicability and Suitability.Pharmaceutics · 2023Article
- Virtual Clinical Trials Guided Design of an Age-Appropriate Formulation and Dosing Strategy of Nifedipine for Paediatric Use.Pharmaceutics · 2023Article
- 3D Printing of Pediatric Medication: The End of Bad Tasting Oral Liquids?-A Scoping Review.Pharmaceutics · 2022Article
- Mini-Tablets: A Valid Strategy to Combine Efficacy and Safety in Pediatrics.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Acceptability of Mebendazole Chewable Tablet in Children Aged 2 to 4 Years in Peru.Pharmaceutics · 2021Article
- Manipulations of Oral Medications in Paediatric Neurology and Oncology Care at a Swedish University Hospital: Health Professionals' Attitudes and Sources of Information.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLiquid medicines are easy to swallow. However, they may have disadvantages, such as a bad taste or refrigerated storage conditions. These disadvantages may be avoided by the use of oral solid medicines, such as powders or tablets. The aim of this study was to investigate the acceptability of and preference among four oral formulations in domiciliary infants and preschool children in The Netherlands.
methodsParents administered four oral placebo dosage forms that were aimed at a neutral taste, at home, to their child (1-4 years of age) twice on one day following a randomised cross-over design: small (4 mm) tablet, powder, suspension and syrup. They were asked to report the child's acceptability by a score on a 10 cm visual analogue scale (VAS score) and by the result of the intake. At the end of the study, they were asked to report the preference of the child and themselves.
results183 children were included and 148 children were evaluated. The data revealed a period/cross-over effect. The estimate of the mean VAS score was significantly higher for the tablet than for the suspension (tablet 9.39/9.01; powder 8.84/8.20, suspension 8.26/7.90, syrup 8.35/8.19; data day 1/all days). The estimate of the mean number of intakes fully swallowed was significantly higher for the tablet than for the other formulations (all p values <0.05). Children and parents preferred the tablet and syrup over the suspension and the suspension over the powder (all p values <0.05).
conclusionsAll formulations were well accepted. The tablets were the best accepted formulation; the tablets and syrup the most preferred. TRIAL REGISTRATION NUMBER: ISRCTN63138435.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.